Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium Sulfate for Neonatal HIE
NCT06342362Phase 4Not yet recruiting
- Sponsor
- Sindh Institute of Child Health and Neonatology
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of magnesium sulfate in hypoxic-ischemic encephalopathy (HIE) (2 arms), sponsored by Sindh Institute of Child Health and Neonatology. Primary endpoint: Neuroprotective effects at 6 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
magnesium sulfate
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06342362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342362.